- Home
- MTNB vs BOLT Comparison
MTNB vs BOLT Comparison
Compare MTNB & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- BOLT
- Stock Information
- Founded
- MTNB 2013
- BOLT 2015
- Country
- MTNB United States
- BOLT United States
- Employees
- MTNB N/A
- BOLT N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- MTNB Health Care
- BOLT Health Care
- Exchange
- MTNB Nasdaq
- BOLT Nasdaq
- Market Cap
- MTNB 9.7M
- BOLT 9.4M
- IPO Year
- MTNB N/A
- BOLT 2021
- Fundamental
- Price
- MTNB $1.73
- BOLT $5.26
- Analyst Decision
- MTNB Hold
- BOLT Buy
- Analyst Count
- MTNB 1
- BOLT 3
- Target Price
- MTNB N/A
- BOLT $47.50
- AVG Volume (30 Days)
- MTNB 118.5K
- BOLT 10.3K
- Earning Date
- MTNB 11-12-2025
- BOLT 11-11-2025
- Dividend Yield
- MTNB N/A
- BOLT N/A
- EPS Growth
- MTNB N/A
- BOLT N/A
- EPS
- MTNB N/A
- BOLT N/A
- Revenue
- MTNB N/A
- BOLT $4,167,000.00
- Revenue This Year
- MTNB N/A
- BOLT N/A
- Revenue Next Year
- MTNB N/A
- BOLT N/A
- P/E Ratio
- MTNB N/A
- BOLT N/A
- Revenue Growth
- MTNB N/A
- BOLT N/A
- 52 Week Low
- MTNB $0.47
- BOLT $4.59
- 52 Week High
- MTNB $4.25
- BOLT $14.36
- Technical
- Relative Strength Index (RSI)
- MTNB 52.72
- BOLT 49.73
- Support Level
- MTNB $1.59
- BOLT $5.04
- Resistance Level
- MTNB $1.88
- BOLT $5.50
- Average True Range (ATR)
- MTNB 0.13
- BOLT 0.23
- MACD
- MTNB -0.04
- BOLT 0.04
- Stochastic Oscillator
- MTNB 28.00
- BOLT 65.42
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.